Content uploaded by Jordan R. Yaron
Author content
All content in this area was uploaded by Jordan R. Yaron on Oct 22, 2020
Content may be subject to copyright.
Pharmaceutics 2020, 12, x; www.mdpi.com/journal/pharmaceutics
Supplementary Materials: Recombinant Myxoma
Virus-Derived Immune Modulator M-T7 Accelerates
Cutaneous Wound Healing and Improves Tissue
Remodeling
Jordan R. Yaron, Liqiang Zhang, Qiuyun Guo, Enkidia A. Awo, Michelle Burgin, Lauren N.
Schutz, Nathan Zhang, Jacquelyn Kilbourne, Juliane Daggett-Vondras,
Kenneth M. Lowe and Alexandra R. Lucas
Figure S1. Quantification of IHC staining for HSP47+ cells per 20× field on tissues of mice on days 4
and 7 post-wounding and treated with saline or M-T7. Statistics analyzed by two-way ANOVA with
Fisher’s LSD post-hoc analysis. All bars are mean and standard error. N = 3–4 mice per treatment per
time point.
Pharmaceutics 2020, 12, x 2 of 2
Figure S2. Full-frame 20× fields of CD4 IHC on Day 7 post-wounding for mice treated with saline and
M-T7. Corresponds to Figure 4H in the main manuscript. Images are representative of 3–4 mice per
treatment.
Figure S3. Quantification of IHC staining for Ly6G+ cells per 20× field on tissues of mice on days 4
and 7 post-wounding and treated with saline or M-T7. Statistics analyzed by two-way ANOVA with
Fiscer’s LSD post-hoc analysis.